Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 9.5%. This drop was worse than the S&P 500’s 2.3% loss.
CONMED CORP has caught the attention as a great value stock. NYSE:CNMD excels in profitability, solvency, and liquidity, all while being very reasonably priced.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including STERIS (NYSE:STE) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Zimmer Biomet (NYSE:ZBH) and the best and worst performers in the surgical equipment & consumables - diversified industry.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - diversified stocks fared in Q4, starting with Solventum (NYSE:SOLV).
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the surgical equipment & consumables - diversified industry, including BD (NYSE:BDX) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at CONMED (NYSE:CNMD) and the best and worst performers in the surgical equipment & consumables - diversified industry.
Medical tech company CONMED (NYSE:CNMD) announced better-than-expected revenue in Q4 CY2024, with sales up 5.8% year on year to $345.9 million. On the other hand, the company’s full-year revenue guidance of $1.36 billion at the midpoint came in 2.7% below analysts’ estimates. Its non-GAAP profit of $1.34 per share was 11.4% above analysts’ consensus estimates.
